DALLAS, June 24, 2020 /PRNewswire/ -- Jacobs (NYSE:J) provided architecture, engineering, construction management and turnover services for a world class biopharmaceutical manufacturing facility, Cruiserath Biologics based in Dublin, Ireland, which, has won the Project Execution category at the International Society for Pharmaceutical Engineering (ISPE) 2020 Facility of the Year Awards (FOYA). The award recognizes innovation in facilities serving the regulated healthcare industry.  The factory, optimized for rapid product changeover and future use as a multi-product facility, will support Bristol Myers Squibb in meeting growing global demand for its medicines.

In 2015, biopharmaceutical manufacturer Bristol Myers Squibb engaged Jacobs to reimagine its existing active pharmaceutical ingredients (API) plant in Dublin, Ireland, to enable large-scale production of its vital immuno-oncology medicines. Representing an innovative approach to fighting cancer, immuno-oncology seeks to harness the body's own immune system to combat tumor cells.

Jacobs was tasked with creating a facility of the future for the $1 billion Multi-Product Cell Culture (MPCC) facility. At the time, the project represented the largest pharmaceutical project being undertaken in Europe, with more than 2,200 people on site at peak. The project's fast-tracked 26-month delivery commanded collaboration from Jacobs' global network of expertise across Ireland, the United States and India, working around the clock to meet the ambitious schedule.

The complexity, scale and speed of execution required game-changing project delivery. A detailed and robust project execution plan was developed to address challenges, monitor progress and ensure project success. The facility was delivered within budget, applying state–of–the–art project delivery techniques and tools, and achieving an impressive safety record during the 6.5 million hours worked. The facility was also awarded LEED Silver certification for its sustainability performance in respect of design, construction and operation. 

"With growing demands for its immuno-oncology medicine, Bristol Myers Squibb needed to build a facility for the future," said Koti Vadlamudi, Jacobs Senior Vice President, Advanced Facilities. "The project is a huge success for Jacobs, Bristol Myers Squibb, and ultimately the many patients that rely on these medicines produced in the Dublin campus."

The facility met the design intent to be a flexible, multi-product manufacturing operation able to produce biopharmaceuticals for human therapeutic use.  The project repurposed an existing site to design and construct a new manufacturing facility, global laboratory, offices, cafeteria, utility and warehouse buildings as one functional campus. The facility is now in commercial operation, having recently received regulatory approval from both the FDA and the European Medicines Authority.

Commenting on the award, Cruiserath Biologics General Manager and Executive Director, EU Biologics, Noel Heaney said, "Cruiserath's campus represents the largest ever capital investment for the company and is the first Bristol Myers Squibb biologics manufacturing facility in Europe. We set out with a vision to build a world class Biopharma Campus and state of the art facility, and to receive this highly coveted external and industry recognition indeed signifies we are well on our way." 

At Jacobs, we're challenging today to reinvent tomorrow by solving the world's most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With $13 billion in revenue and a talent force of more than 55,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter.

Certain statements contained in this press release constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements, including, but not limited to, the impact of the COVID-19 pandemic and the related reaction of governments on global and regional market conditions and the company's business. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our Annual Report on Form 10-K for the year ended September 27, 2019, and in particular the discussions contained under Item 1 - Business; Item 1A - Risk Factors; Item 3 - Legal Proceedings; and Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations, as well as the company's other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

For press/media inquiries: 
Kerrie Sparks 
214.583.8433

Jacobs Logo (PRNewsfoto/Jacobs)

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/jacobs-designed-and-built-multi-product-cell-culture-mpcc-facility-wins-international-society-for-pharmaceutical-engineering-facility-of-the-year-award-301080612.html

SOURCE Jacobs